TABLE 1.
In vitro susceptibilities of strains used in hollow-fiber studies
Strain | β-Lactamase(s) | Regimensa | MIC (μg/ml) |
|||
---|---|---|---|---|---|---|
Ceftazidime | Avibactam | Ceftazidime + 4 μg/ml avibactam | Ceftazidime-avibactam at 4:1 | |||
E. cloacae 293HT96 | Stably derepressed AmpC | 1, 2, 3 | >128 | >32 | 4 | 8:2 |
K. pneumoniae Tunisie K4 | CTX-M-15, TEM-1b, OXA-1b | 1, 2 | >128 | >32 | 1 | 4:1 |
K. pneumoniae 283KB5 | SHV-11, AmpC | 1, 2 | >128 | >32 | 0.5 | NTc |
K. pneumoniae 283CF5 | SHV-5 | 1, 2 | 64 | >32 | 2 | NT |
K. pneumoniae 181 | SHV-5, TEM-10 | 1, 2 | >128 | >32 | 2 | 8:2 |
K. pneumoniae 236 | SHV-5, TEM-10 | 1, 2 | >128 | >32 | 2 | 1:0.25 |
K. pneumoniae 5761 | KPC-3 | 1, 3 | >128 | >32 | 4 | 8:2 |
Citrobacter freundii 261GR3 | AmpC, TEM-1b | 1, 2 | >128 | >32 | ≤0.125 | 2:0.5 |
Dosing regimens for which this organism was used (see the text for further details).
β-Lactamase does not hydrolyze ceftazidime to any great extent.
NT, not tested.